(UroToday.com) There has been a proliferation in treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) in the last 10 years. While there are many available treatment options, to date, we have been unable to widely operationalize rationale treatment selection. This has been limited in large part by the lack of head-to-head trials in this disease space. In the Prostate, Testicular, Penile Poster session at the 2021 American Society of Clinical Oncology Annual Meeting, Dr. Kim van der Zande presented results of the OSTRICh trial which randomized patients with poor-prognosis mCRPC following progression on docetaxel to cabazitaxel or an androgen receptor-targeted agent.